Eisai


Healthcare

Treatment choice.

In early 2015, Eisai Pharmaceuticals launched lenvatinib, a triple-targeting tyrosine kinase inhibitor for the treatment of radioiodine refractory differentiated thyroid cancer. The Eisai oncology team wanted to develop a functional sales aid that would challenge the way physicians make their treatment choices.

Blue Dog worked with the Lenvatinib team at Eisai to design and produce a Microsoft Surface Pro application for the field force. The app is designed to help a sales representative guide a physician through a complex treatment decision algorithm, challenging their current prescribing behaviour. Users are guided through a series of flexible treatment decisions, which can be tailored towards a particular patient profile. The application also includes a comprehensive reporting tool, which allows the user to email a pdf meeting summary to the physician following the session.